globenewswire

Exoben invites U.S. investors to join its private round powering gold recovery, solar grids, and advanced battery tech across Ghana and the U.S.

The Methicillin-resistant Staphylococcus Aureus (MRSA) Epidemiology Forecast Report 2025-2034 offers a detailed analysis of MRSA's prevalence and associated demographic factors. It examines incidence trends, treatment challenges, and regional disparities across key markets, providing crucial insights into MRSA's global health impact.

FORM 8.5 (EPT/RI)

All amounts presented in this release are in U.S. Dollar (“USD”) unless otherwise stated.

Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasury

MIGDAL HAEMEK, Israel – July 14, 2025 – Tower Semiconductor (NASDAQ/ TASE: TSEM), the leading foundry of high value analog semiconductor solutions, will issue its second quarter 2025 earnings release on Monday, August 4, 2025. The Company will hold a conference call to discuss its second quarter 2025 financial results and third quarter 2025 guidance on Monday, August 4, 2025, at 10:00 a.m. Eastern Time (09:00 a.m. Central, 08:00 a.m. Mountain, 07:00 a.m. Pacific and 05:00 p.m. Israel time).

Í 28. viku 2025 keypti Nova Klúbburinn hf. 3.000.000 eigin hluti að kaupverði 14.640.000 kr. í samræmi við eftirfarandi:

ROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascentage” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that Dajun Yang Dynasty Trust, an affiliate of the Company’s Chief Executive Officer, Dajun Yang, M.D., Ph.D. (the “Vendor”), proposes to offer ordinary shares, par value US$0.0001 per share, of the Company (the “Placement Shares”) in an offshore transaction outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors (the “Offshore Placement”). At the time of the closing of the Offshore Placement, the Vendor would subscribe for, and the Company would issue to the Vendor new ordinary shares of the Company (the “Replacement Shares”) at the same number as the number of the Placement Shares offered in the Offshore Placement and at the same price per share as the price per share for the Placement Shares. The closing of the transaction involving the issuance of the Replacement Shares will be subject to customary closing conditions and take place after the closing of the Offshore Placement. In connection with the Offshore Placement, the representatives in the Company’s U.S. initial public offering in January 2025 waived a lock-up restriction with respect to the Placement Shares held by the Vendor.

In week 28 of 2025, Kaldalón hf. purchased 2,544,345 of its own shares for a total consideration of ISK 61,909,963, as detailed below:

Í viku 28 árið 2025 keypti Kaldalón hf. 2.544.345 eigin hluti að kaupvirði kr. 61.909.963 skv. sundurliðun hér á eftir;

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.